Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 6Phase 1 3Phase 4 2Phase 1/2 2Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Genitourinary 1

Conditions

Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Renal Cell 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Interventional × Interferons × Clear all
NCT00352859 2014-12-30

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Bayer

Phase 4 Terminated
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT00390897 2008-11-27

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

PETHEMA Foundation

Phase 4 Completed
360 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡